Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

亚虹医药公告称，子公司Asieris Pharmaceuticals(Aus)Pty Ltd收到澳大利亚相关机构批准，产品APL - 2401（药物名ASN - 8639片）获在澳开展Ⅰ期临床试验许可并完成备案。APL - 2401是自主研发的 FGFR2/3双靶点小分子抑制剂，此前已获国家药监局临床试验批准。该产品有望为晚期实体瘤患者提供 新疗法，相比同类产品有潜在优势。不过，此次获批对近期业绩无重大影响，研发存在不确定性。 ...

Core Viewpoint - Asieris Pharmaceuticals has received ethical approval for its product APL-2401 to conduct Phase I clinical trials in Australia for patients with advanced solid tumors driven by FGFR2/3 [1] Group 1: Clinical Trial Approval - The company’s subsidiary, Asieris Pharmaceuticals (Aus) Pty Ltd, has obtained ethical approval from the Human Research Ethics Committee in Australia for APL-2401 [1] - The clinical trial has also been registered with the Therapeutic Goods Administration, the Australian drug regulatory authority [1] - APL-2401 has previously received approval from the National Medical Products Administration in China, indicating the company's commitment to advancing international multi-center clinical research [1] Group 2: Product Overview - APL-2401 is a highly selective small molecule inhibitor targeting FGFR2/3, developed to provide new treatment options for patients with advanced solid tumors such as urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [1] - The drug was optimized through the TAIDD platform, focusing on its selective mechanism for compound discovery and design [2] - APL-2401 demonstrates superior dual kinase inhibition activity compared to existing FGFR2 or FGFR3 selective inhibitors, with enhanced tumor cell killing and tumor microenvironment modulation effects [2] Group 3: Safety and Efficacy - Preclinical studies indicate that APL-2401 shows excellent efficacy and a wider safety window across various FGFR2/3 gene mutation, amplification, or overexpression models [2] - Compared to pan-FGFR inhibitors, APL-2401 significantly reduces the side effects associated with FGFR1 and FGFR4 [2] - The product exhibits potential best-in-class advantages in terms of activity, selectivity, safety, and druggability within the FGFR2/3 targeted therapy field [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688176 证券简称：亚虹医药 公告编号：2026-003 重要内容提示： 近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）子公司 Asieris Pharmaceuticals (Aus) Pty Ltd 收到澳大利亚人类研究伦理委员会签发的关于批准 公司开发的产品 APL-2401（药物名称为 ASN-8639 片）在 FGFR2/3 驱动的晚期 实体瘤患者中开展Ⅰ期临床试验的临床试验伦理许可，并于澳大利亚卫生部所属 的 Therapeutic Goods Administration（即澳大利亚药品管理局）完成临床试验备 案。按照澳大利亚药品注册相关法律法规，公司已获得该产品 I 期临床试验许可。 此前 APL-2401 临床试验申请已获得国家药品监督管理局批准，公司将积极推进 该产品的国际多中心临床研究。 江苏亚虹医药科技股份有限公司 自愿披露关于 APL-2401 在澳大利亚获得开展Ⅰ期临床 试验许可的公告 1 CTN 号：CT-2025-CTN- ...

证券日报网1月21日讯，亚虹医药在接受调研者提问时表示，国家药品监督管理局药品审评中心(CDE) 已完成APL-1702的技术评审，公司将加快推进其上市审评审批工作，以期尽快获得上市批准。关于后 续进展，公司将严格按照《上海证券交易所科创板股票上市规则》等相关规定履行信息披露义务。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. plans to utilize part of its temporarily idle raised funds for cash management, aiming to enhance fund efficiency while ensuring the safety of the raised funds and the implementation of investment projects [1][2]. Cash Management Overview - The company intends to use a maximum of RMB 1.2 billion (including the amount) of temporarily idle raised funds for cash management, with a validity period of 12 months from the date of the board's approval [2][8]. - The cash management aims to increase returns for the company and its shareholders while not affecting the normal operation of the fundraising investment projects [2][12]. Investment Details - The investment will focus on high-security, high-liquidity financial products sold by qualified financial institutions, including agreement deposits, time deposits, notice deposits, large certificates of deposit, structured deposits, and income certificates [4][8]. - The company will not use these funds for securities investment purposes [4]. Implementation and Oversight - The board has authorized the chairman to make investment decisions and sign relevant contracts within the approved limits and timeframe, with the finance department responsible for implementation [5][8]. - The company will adhere to strict regulatory requirements and maintain a separation of decision-making, execution, and supervision functions to ensure fund safety [10]. Impact on the Company - The use of temporarily idle raised funds for cash management is expected to improve fund efficiency and provide good investment returns for the company and its shareholders, without affecting daily cash flow needs or the normal operation of fundraising projects [12]. Opinions from Intermediaries - The sponsor, CITIC Securities Co., Ltd., has reviewed the cash management plan and found it compliant with relevant laws and regulations, expressing no objections to the company's decision [12].

证券代码：688176 证券简称：亚虹医药 公告编号：2026-002 江苏亚虹医药科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）于 2026 年 1 月 16 日召开第二届董事会第二十次会议，审议通过了《关于使用部分 暂时闲置募集资金进行现金管理的议案》，同意公司在保证不影响募集资金投资 项目实施、募集资金安全的前提下，使用部分暂时闲置募集资金进行现金管理， 用于购买安全性高、流动性好、有保本约定、具有合法经营资格的金融机构销售 的投资产品，使用期限自本次董事会审议通过之日起 12 个月内有效，在前述额 度及期限范围内，公司可以循环滚动使用。 董事会授权董事长在授权额度和期限内行使现金管理投资决策权并签署相 关合同文件，具体事项由公司财务部负责组织实施。保荐人中信证券股份有限公 司（以下简称"保荐人"）对上述事项出具了核查意见。本事项无需提交股东会 审议。现将公司本次使用部分闲置募集资金进行现金管 ...

中信证券股份有限公司关于江苏亚虹医药科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）为江苏亚虹 医药科技股份有限公司（以下简称"公司"、"亚虹医药"）首次公开发行股票 并上市的保荐人。根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》等相关法律、法规和规范性文件的规定， 对亚虹医药使用部分暂时闲置募集资金进行现金管理事项进行了核查，核查情况 及核查意见如下： 一、募集资金基本情况 （三）资金来源 | 发行名称 | 公司首次公开发行股票 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 募集资金到账时间 | 2021 年 12 月 31 | | | 日 | | | | | | 募集资金总额 | 252,780.00 | | 万元 | | | | | | | 募集资金净额 | 万元 238,059.22 | | | | | | ...

Core Viewpoint - The company, Yahuang Pharmaceutical, has announced the approval of a proposal to use up to 1.2 billion yuan of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [1] Group 1: Financial Management - The board of directors approved the use of idle funds for cash management, with a maximum limit of 1.2 billion yuan [1] - The investment products will be purchased from financial institutions that offer high safety, good liquidity, and capital protection agreements [1] - The usage period for these funds is valid for 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] Group 2: Impact on Operations - This decision will not affect the progress of the fundraising investment projects or the normal production and operation of the company [1]